Everything tagged "biotechnology" across the TickerSpark archives.
Abivax is a catalyst-driven biotech centered on obefazimod, with long-term ulcerative colitis durability data and a cash runway into Q4 2027. The stock offers meaningful upside if Phase 3 execution holds, but the valuation already prices in a lot of success.
Summit Therapeutics is a high-risk, high-upside oncology story centered on ivonescimab and a November 2026 FDA decision. The stock offers meaningful regulatory upside, but the business still has no product revenue and remains dependent on one drug.
Roivant Sciences is a cash-rich biotech platform with a near-term brepocitinib launch and several late-stage catalysts, but valuation already reflects meaningful execution risk. The stock is a Hold as investors wait for commercial proof and clinical readouts.
Alnylam has crossed into profitable commercial-stage biotech, powered by AMVUTTRA and a fast-growing TTR franchise. Valuation is rich, but the company’s revenue growth, cash generation, and pipeline support a Buy rating.
OTLK's $5.81 million insider buying is a real vote of confidence, but the company is still funding an approved product with fresh equity. A $55 million stock-and-warrant offering, a 600 million share authorization and ongoing losses keep dilution ahead of durable commercial proof.
BioNTech is moving from fading COVID-19 vaccine revenue to a multi-product oncology pipeline, but near-term earnings remain weak. Its cash-rich balance sheet supports the transition, yet the stock still depends on late-stage clinical execution.
Vertex is executing well across cystic fibrosis, with ALYFTREK, CASGEVY, and JOURNAVX all contributing to growth while the renal pipeline and Crinetics deal broaden the story. The stock earns a Buy on durable cash generation and a fair value estimate of $560.
Attovia's insider signal is bullish, but the cleanly supported figure is $10.29 million rather than the touted $20.57 million. The smaller number still matters because it arrived alongside a roughly $289 million IPO and a lead asset already tested in humans.
argenx has turned VYVGART into a fast-growing, cash-generating immunology franchise with expanding label breadth and a deepening pipeline. The stock still trades at a premium, but the report argues the commercial momentum supports a Buy.
Braveheart Bio has a credible bull case as insider-aligned capital backs a lead program with positive Phase 2 data and a late-stage path. The single-asset risk is real, but the size of recent buying makes today’s IPO pullback look more like volatility than a thesis break.
Moderna is a Hold as mNEXSPIKE gains traction and the pipeline advances, but shrinking revenue, heavy losses, and negative free cash flow keep the story high risk.
Insmed is transitioning from cash-burning biotech to a commercial respiratory growth story, powered by BRINSUPRI’s rapid launch and improving margins. The stock looks attractive on execution, but valuation already reflects meaningful success.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime